Moreover, ADT was shown to be a key driver of the neuroendocrine differentiation of the prostate adenocarcinoma to NEPC [8], and so it is not surprising that the incidence of treatment-induced NEPC is rising because of the widespread use of more potent androgen receptor (AR) pathway inhibitors [9]. This evidence concerns the gene AR and prostate adenocarcinoma.